These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31255259)

  • 41. Limited family structure and BRCA gene mutation status in single cases of breast cancer.
    Weitzel JN; Lagos VI; Cullinane CA; Gambol PJ; Culver JO; Blazer KR; Palomares MR; Lowstuter KJ; MacDonald DJ
    JAMA; 2007 Jun; 297(23):2587-95. PubMed ID: 17579227
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
    Doren A; Vecchiola A; Aguirre B; Villaseca P
    Climacteric; 2018 Dec; 21(6):529-535. PubMed ID: 30295091
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
    Ghezelayagh TS; Pennington KP; Norquist BM; Khasnavis N; Radke MR; Kilgore MR; Garcia RL; Lee M; Katz R; Leslie KK; Risques RA; Swisher EM
    Gynecol Oncol; 2021 Mar; 160(3):786-792. PubMed ID: 33375991
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: a retrospective study in a sample of Italian cancer genetics clinics.
    Varesco L; Viassolo V; Viel A; Gismondi V; Radice P; Montagna M; Alducci E; Della Puppa L; Oliani C; Tommasi S; Caligo MA; Vivanet C; Zuradelli M; Mandich P; Tibiletti MG; Cavalli P; Lucci Cordisco E; Turchetti D; Boggiani D; Bracci R; Bruzzi P; Bonelli L
    Breast; 2013 Dec; 22(6):1130-5. PubMed ID: 24011770
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multigene panel testing results in patients with multiple breast cancer primaries.
    Corredor J; Woodson AH; Gutierrez Barrera A; Arun B
    Breast J; 2020 Jul; 26(7):1337-1342. PubMed ID: 31999039
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network.
    Weitzel JN; Clague J; Martir-Negron A; Ogaz R; Herzog J; Ricker C; Jungbluth C; Cina C; Duncan P; Unzeitig G; Saldivar JS; Beattie M; Feldman N; Sand S; Port D; Barragan DI; John EM; Neuhausen SL; Larson GP
    J Clin Oncol; 2013 Jan; 31(2):210-6. PubMed ID: 23233716
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
    Bayraktar S; Gutierrez-Barrera AM; Liu D; Tasbas T; Akar U; Litton JK; Lin E; Albarracin CT; Meric-Bernstam F; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK
    Breast Cancer Res Treat; 2011 Nov; 130(1):145-53. PubMed ID: 21830012
    [TBL] [Abstract][Full Text] [Related]  

  • 49. What is the appropriate genetic testing criteria for breast cancer in the Chinese population?-Analysis of genetic and clinical features from a single cancer center database.
    Ni M; Wang F; Yang A; Shao Q; Xue C; Xia W; Xu F; Lin X; Huang J; Bi X; Hong R; Chen M; Zheng Q; Jiang K; Xie X; Tang J; Wang X; Yuan Z; Wang S; Shi Y; An X
    Cancer Med; 2023 Jun; 12(12):13019-13030. PubMed ID: 37096751
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
    Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
    Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
    Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME
    Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany.
    Hamann U; Liu X; Bungardt N; Ulmer HU; Bastert G; Sinn HP
    Eur J Hum Genet; 2003 Jun; 11(6):464-7. PubMed ID: 12774040
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer.
    Grant RC; Holter S; Borgida A; Dhani NC; Hedley DW; Knox JJ; Akbari MR; Zogopoulos G; Gallinger S
    J Genet Couns; 2018 Aug; 27(4):988-995. PubMed ID: 29441441
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of the indication of BRCA1/2 genetic tests in Iranian women and acceptance rate of risk-reducing surgeries in BRCA mutation carriers.
    Vasigh M; Eslami B; Elahi A; Kaviani A; Shirkoohi R; Majidzadeh K; Nazarian N; Omranipour R
    Mol Genet Genomic Med; 2022 Feb; 10(2):e1867. PubMed ID: 35023322
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lymphocyte telomere length is long in BRCA1 and BRCA2 mutation carriers regardless of cancer-affected status.
    Pooley KA; McGuffog L; Barrowdale D; Frost D; Ellis SD; Fineberg E; Platte R; Izatt L; Adlard J; Bardwell J; Brewer C; Cole T; Cook J; Davidson R; Donaldson A; Dorkins H; Douglas F; Eason J; Houghton C; Kennedy MJ; McCann E; Miedzybrodzka Z; Murray A; Porteous ME; Rogers MT; Side LE; Tischkowitz M; Walker L; Hodgson S; Eccles DM; Morrison PJ; Evans DG; Eeles RA; Antoniou AC; Easton DF; Dunning AM;
    Cancer Epidemiol Biomarkers Prev; 2014 Jun; 23(6):1018-24. PubMed ID: 24642354
    [TBL] [Abstract][Full Text] [Related]  

  • 56. More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling.
    Sie AS; van Zelst-Stams WA; Spruijt L; Mensenkamp AR; Ligtenberg MJ; Brunner HG; Prins JB; Hoogerbrugge N
    Fam Cancer; 2014 Jun; 13(2):143-51. PubMed ID: 24068317
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
    Atchley DP; Albarracin CT; Lopez A; Valero V; Amos CI; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK
    J Clin Oncol; 2008 Sep; 26(26):4282-8. PubMed ID: 18779615
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
    Straub MM; Podoll MB; David SN; Wiesner GL; Desouki MM
    Ann Diagn Pathol; 2018 Oct; 36():28-30. PubMed ID: 30055521
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer.
    Chiba A; Hoskin TL; Hallberg EJ; Cogswell JA; Heins CN; Couch FJ; Boughey JC
    Ann Surg Oncol; 2016 Oct; 23(10):3232-8. PubMed ID: 27338744
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review.
    Huber D; Seitz S; Kast K; Emons G; Ortmann O
    Arch Gynecol Obstet; 2020 Sep; 302(3):715-720. PubMed ID: 32719921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.